Uses of Intatacro

Intatacro is a drug that affects the immune system. With the main ingredient being Tacrolimus, Intatacro is used in patients after organ transplant surgery such as liver, kidney, heart.

Intatacro belongs to the group of drugs that affect the immune system, with the main ingredient being Tacrolimus (as Tacrolimus monohydrate) 0.5mg. Tacrolimus has strong immunosuppressive effects and suppresses T lymphocytes. For grafts such as liver, kidney, heart, bone marrow, pancreas, small intestine, lung, trachea, skin, cornea and extremities, Tacrolimus helps prolong life.
Intatacro is made in the form of hard capsules and is indicated for use in the following cases:
Prophylactic treatment of transplant type for patients undergoing liver, kidney or heart transplant surgery. Transplant therapy for immunosuppressive drug-resistant transplant patients.

Intatacro is taken orally. Take the drug with water and = 1 hour before meals or 2-3 hours after meals to maximize drug absorption.
Dosage of Intatacro in adults is as follows:
Liver transplant: Initial dose is from 100-200mcg/kg body weight/day, divided into 2 oral doses a day. Heart transplant: Initial dose is 75 mcg/kg body weight/day, divided into 2 oral doses a day. Kidney transplant: The initial dose is 150-300 mcg/kg body weight/day, divided into 2 oral doses a day. Dosage of Intatacro in children is as follows:
Liver and kidney transplant: Initial dose is 300 mcg/kg body weight/day, divided into 2 oral doses per day. Duration of administration: For liver and heart transplants, take the drug within about 6 hours immediately after the transplant surgery is complete, and for kidney transplants, 24 hours. The maintenance dose of Intatacro should be adjusted depending on the trough concentration of tacrolimus in plasma or whole blood for the individual patient. Most patients respond well to tacrolimus whole blood concentrations maintained below 20 ng/ml. For children, to achieve this value, a larger dose of 1.5 - 2 times is required.
Although there is not enough information on overdose, overdose of Intatacro can cause symptoms such as nausea, vomiting, headache, tremor, lethargy, hives, infection, increased blood urea, serum creatinine and alanine aminotransferase concentrations.
There is currently no specific antidote for Intatacro overdose. In this case, the patient should receive symptomatic treatment and support if necessary. Hemodialysis does not remove the drug; instead, activated charcoal or intestinal lavage can be used to treat poisoning if the drug is recently taken. Hemodialysis or hemodialysis may be effective in reducing concentrations in patients with very high plasma concentrations.

Intatacro is mainly toxic to the nervous system and kidneys. The drug can cause some unwanted effects with the frequency of occurrence as follows:
Common: Nausea, diarrhea, headache, tremor, paresthesia; renal failure, anemia, hypertension, leukopenia, thrombocytopenia; hyperkalemia, electrolyte disturbances. Uncommon: Intatacro rarely causes tinnitus, dizziness, visual disturbances, sleep disturbances, mood swings, confusion, convulsions; diabetes, disorders of carbohydrate metabolism; tachycardia, ECG changes, myocardial hypertrophy; indigestion, constipation, gastrointestinal bleeding; asthma, shortness of breath, pleural effusion; itching, skin rash, hirsutism, hair loss; muscle pain, joint pain, cramps; coagulation disorders/liver function, peripheral edema. If you see any strange symptoms after taking Intatacro, the patient should immediately notify the treating doctor or go to a medical facility for a health check.

Do not use Intatacro in people who are hypersensitive to any of its ingredients or Macrolide. For patients with hepatic or renal impairment, it may be necessary to adjust the dose of Intatacro and monitor blood levels of Tacrolimus in the patient. After transplant surgery, in the first phase of Intatacro use, it is necessary to monitor parameters including: ECG, blood pressure, nerve and vision, liver and kidney function, blood glucose, electrolytes, blood count and coagulation indices, plasma proteins. If clinically abnormal, adjustment to immunosuppressive therapy should be considered. Intatacro in particular and immunosuppressants in general can increase the risk of infection and malignancy. Therefore, caution should be exercised when using intrauterine devices and during administration without vaccination with live vaccines. While taking Intatacro, the patient must not drive, drive or operate machinery because the drug can affect vision and nervous system. Pregnant women are only allowed to use Intatacro in cases where it is absolutely necessary and very cautious because the drug can affect the baby after birth such as kidney damage, hyperkalemia. Breastfeeding women who want to take the drug should stop breastfeeding. Avoid concomitant use of Intatacro with potentially nephrotoxic drugs such as ciclosporin as it may increase nephrotoxicity. Do not use Intatacro at the same time as potassium-sparing diuretics. Avoid concomitant use of Intatacro with enzyme inhibitors such as antifungal drugs, calcium channel blockers, corticosteroids, HIV-protease inhibitors, antibiotics of the Macrolide and Metoclopramide group, Delavirdine because it may increase the concentration of Tacrolimus in the blood. blood. In contrast, concentrations of Tacrolimus decreased when co-administered with inducers of cytochrome P450 isoenzyme CYP3A4 For food, do not take Intatacro with grapefruit juice because this drink also inhibits the metabolism of Tacrolimus. The use of Intatacro is to suppress immunosuppression and T-lymphocytes for the prevention of transplantation in patients with liver, kidney, or heart transplants or to treat transplantation in immunocompromised transplant patients. To ensure safety for your health and maximize the effectiveness of your treatment, you need to take Intatacro exactly as directed by your doctor.